Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SABS NASDAQ:VTVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSABSSAB Biotherapeutics$3.55-0.3%$3.85$1.60▼$6.60$181.39M0.551.09 million shs488,017 shsVTVTvTv Therapeutics$36.49+2.8%$35.94$14.00▼$44.00$139.79M0.2659,572 shs65,401 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSABSSAB Biotherapeutics-0.28%-1.93%-7.79%-5.08%+97.22%VTVTvTv Therapeutics+2.82%+13.64%-4.28%-1.99%+71.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSABSSAB Biotherapeutics$3.55-0.3%$3.85$1.60▼$6.60$181.39M0.551.09 million shs488,017 shsVTVTvTv Therapeutics$36.49+2.8%$35.94$14.00▼$44.00$139.79M0.2659,572 shs65,401 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSABSSAB Biotherapeutics-0.28%-1.93%-7.79%-5.08%+97.22%VTVTvTv Therapeutics+2.82%+13.64%-4.28%-1.99%+71.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSABSSAB Biotherapeutics 2.75Moderate Buy$11.00209.86% UpsideVTVTvTv Therapeutics 2.86Moderate Buy$53.0045.25% UpsideCurrent Analyst Ratings BreakdownLatest VTVT and SABS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026VTVTvTv Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/13/2026VTVTvTv Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/12/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.005/11/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/10/2026SABSSAB Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/2/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.003/27/2026VTVTvTv Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026VTVTvTv Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.003/12/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/12/2026VTVTvTv Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSABSSAB Biotherapeutics$1.32M137.02$0.34 per share10.42$4.46 per share0.80VTVTvTv Therapeutics$1.02M140.95N/AN/A$22.84 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSABSSAB Biotherapeutics$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%8/6/2026 (Estimated)VTVTvTv Therapeutics-$26.97M-$0.93N/AN/AN/AN/A3.96%2.86%N/ALatest VTVT and SABS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026VTVTvTv Therapeutics$0.21$1.65+$1.44$1.65$20.00 million$36.84 million5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A3/10/2026Q4 2025VTVTvTv Therapeutics-$1.0880-$0.58+$0.5080-$0.58N/AN/A3/9/2026Q4 2025SABSSAB Biotherapeutics-$0.16-$0.46-$0.30-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthSABSSAB BiotherapeuticsN/AN/AN/AN/AN/AVTVTvTv TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSABSSAB Biotherapeutics0.0111.4511.45VTVTvTv TherapeuticsN/A14.3614.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSABSSAB Biotherapeutics7.82%VTVTvTv Therapeutics17.51%Insider OwnershipCompanyInsider OwnershipSABSSAB Biotherapeutics25.06%VTVTvTv Therapeutics5.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSABSSAB Biotherapeutics14050.95 million38.18 millionNot OptionableVTVTvTv Therapeutics93.94 million3.70 millionNot OptionableVTVT and SABS HeadlinesRecent News About These CompaniesvTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen NextMay 17 at 1:53 PM | finance.yahoo.comWhy vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%May 16, 2026 | aaii.comAvTv Therapeutics (NASDAQ:VTVT) Upgraded at Zacks ResearchMay 16, 2026 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Raised to Buy at Wall Street ZenMay 16, 2026 | americanbankingnews.comvTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be SustainableMay 15, 2026 | zacks.comvTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 15, 2026 | americanbankingnews.comvTv Therapeutics Expands At-The-Market Share Program CapacityMay 13, 2026 | tipranks.comvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comvTv Therapeutics (VTVT) Projected to Post Earnings on WednesdayMay 11, 2026 | marketbeat.comvTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by AnalystsMay 10, 2026 | marketbeat.comvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comvTv Therapeutics to Participate in Upcoming May Investor ConferencesMay 7, 2026 | globenewswire.comvTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving Average - What's Next?May 6, 2026 | marketbeat.comvTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest UpdateApril 28, 2026 | marketbeat.comvTv Therapeutics (NASDAQ:VTVT) Stock Passes Below Fifty Day Moving Average - Time to Sell?April 24, 2026 | marketbeat.comWall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?April 20, 2026 | zacks.comvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 7, 2026 | globenewswire.comvTv Therapeutics, Inc. Class AApril 6, 2026 | edition.cnn.comWall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a BetApril 2, 2026 | zacks.comvTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin AdvancementsMarch 17, 2026 | insidermonkey.comWall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to TradeMarch 17, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTVT and SABS Company DescriptionsSAB Biotherapeutics NASDAQ:SABS$3.55 -0.01 (-0.28%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$3.60 +0.06 (+1.55%) As of 05/19/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.vTv Therapeutics NASDAQ:VTVT$36.49 +1.00 (+2.82%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$36.70 +0.21 (+0.59%) As of 05/19/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
